Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells

Vascular Pharmacology

Volumn 53, Issue 5-6, 2010, Pages 209-214

  Keltai, Katalin ^a   Cervenak, László ^b   Makó, Veronika ^a   Doleschall, Zoltán ^c   Zsáry, András ^a   Karádi, István ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Doxorubicin; Endothelial cells; Endothelin 1; Gene array; Gene expression

Indexed keywords

DOXORUBICIN; ENDOTHELIN 1; MESSENGER RNA;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN;

ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; RNA, MESSENGER; UMBILICAL VEINS;

EID: 78349307779     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.08.001     Document Type: Article

References (44)

1. Abou El Hassan M.A., Verheul H.M., et al. The new cardioprotector monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. Br. J. Cancer 2003, 89:357-362.
2. Agapitov A.V., Haynes W.G. Role of endothelin in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 2002, 3:1-15.
3. Aroui S., Brahim S., et al. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell penetrating peptides in different cell lines: a comparative Study. Biochem. Biophys. Res. Commun. 2010, 391(1):419-425.
4. Bagnato A., Spinella F., et al. Emerging role of the endothelin axis in ovarian tumor progression. Endocr. Relat. Cancer 2005, 12:761-772.
5. Bien S., Riad A., et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007, 67:10428-10435.
6. Boulanger C., Luscher T.F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 1990, 85:587-590.
7. Chen X.P., Xun K.L., et al. Oxidized low density lipoprotein receptor-1 mediates oxidized low density lipoprotein-induced apoptosis in human umbilical vein endothelial cells: role of reactive oxygen species. Vascular Pharmacol. 2007, 47:1-9.
8. Cosse J.P., Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem. 2008, 8:790-797.
9. Damrot J., Nubel T., et al. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol. 2006, 149:988-997.
10. Davenport A., Maguire J. Endothelin. Handb. Exp. Pharmacol. 2006, 176(Pt 1):295-329.
11. Didier N., Banks W.A., et al. HIV-1-induced production of endothelin-1 in an in vitro model of the human blood-brain barrier. NeuroReport 2002, 13:1179-1183.
12. Dong F., Zhang X., et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br. J. Pharmacol. 2005, 145:323-333.
13. Dorfman D.M., Wilson D.B., et al. Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J. Biol. Chem. 1992, 267:1279-1285.
14. Guise T.A., Kozlow W.M., et al. Molecular mechanisms of breast cancer metastases to bone. Clin. Breast Cancer 2005, 5(Suppl):S46-S53.
15. Herczenik E., Varga Z., et al. Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. J. Recept. Signal Transduct. Res. 2009, 29:75-83.
16. Herrmann E., Bogemann M., et al. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Rev. Anticancer Ther. 2006, 6:73-81.
17. Kaushal V., Kaushal G.P., et al. Differential toxicity of anthracyclines on cultured endothelial cells. Endothelium 2004, 11:253-258.
18. Keltai K., Vago H., et al. Endothelin gene expression during ischemia and reperfusion. J. Cardiovasc. Pharmacol. 2004, 44:S198-S201.
19. Knowles J., Loizidou M., et al. Endothelin-1 and angiogenesis in cancer. Curr. Vasc. Pharmacol. 2005, 3:309-314.
20. Kreuzer K.A., Lass U., et al. Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin. Chem. 1999, 45:297-300.
21. Layon M.E., Ackley C.J., et al. Expression of GATA-1 in a non-hematopoietic cell line induces beta-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression. J. Mol. Biol. 2007, 366:737-744.
22. Lee M.E., Dhadly M.S., et al. Regulation of endothelin-1 gene expression by Fos and Jun. J. Biol. Chem. 1991, 266:19034-19039.
23. Lovric-Bencic M., Sikiric P., et al. Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. J. Pharmacol. Sci. 2004, 95:19-26.
24. Luscher T.F., Boulanger C.M., et al. Endothelium-derived contracting factors. Hypertension 1992, 19:117-130.
25. Masaki T. Historical review: endothelin. Trends Pharmacol. Sci. 2004, 25:219-224.
26. Mawji I.A., Marsden P.A. RNA transfection is a versatile tool to investigate endothelin-1 posttranscriptional regulation. Exp. Biol. Med. (Maywood) 2006, 231:704-708.
27. Mostafa M.G., Mima T., et al. Doxorubicin, an RNA synthesis inhibitor, prevents vasoconstriction and inhibits aberrant expression of endothelin-1 in the cerebral vasospasm model of the rat. Neurosci. Lett. 2000, 283:197-200.
28. Ogata Y., Takahashi M., et al. Antiapoptotic effect of endothelin-1 in rat cardiomyocytes in vitro. Hypertension 2003, 41:1156-1163.
29. Oroszlan M., Herczenik E., et al. Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP. Int. Immunol. 2006, 18:871-878.
30. Rahman A., Carmichael D., et al. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 1986, 46:2295-2299.
31. Riad A., Bien S., et al. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur. J. Heart Fail. 2008, 10:233-243.
32. Salani D., Taraboletti G., et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 2000, 157:1703-1711.
33. Sayed-Ahmed M.M., Khattab M.M., et al. Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol. Toxicol. 2001, 89:140-144.
34. Shichiri M., Sedivy J.M., et al. Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol. Endocrinol. 1998, 12:172-180.
35. Smollich M., Wulfing P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr. Vasc. Pharmacol. 2007, 5:239-248.
36. Spallarossa P., Fabbi P., et al. Doxorubicin-induced expression of LOX-1 in H9c2 cardiac muscle cells and its role in apoptosis. Biochem. Biophys. Res. Commun. 2005, 335:188-196.
37. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 2007, 49:330-352.
38. Ueno M., Kakinuma Y., et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J. Pharmacol. Sci. 2006, 101:151-158.
39. Wolf M.B., Baynes J.W. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim. Biophys. Acta 2006, 1760:267-271.
40. Woodley-Cook J., Shin L.Y., et al. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol. Cancer Ther. 2006, 5:3303-3311.
41. Yamashita J., Ogawa M., et al. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int. J. Cancer 1995, 62:542-547.
42. Zhao B., Stavchansky S.A., et al. Effect of interleukin-1beta and tumor necrosis factor-alpha on gene expression in human endothelial cells. Am. J. Physiol. Cell Physiol. 2003, 284:C1577-C1583.
43. Zsary A., Szucs S., et al. Endothelin-1 and cardiac function in anthracycline-treated patients: a 1-year follow-up. J. Cardiovasc. Pharmacol. 2004, 44(Suppl 1):S372-S375.
44. Zsary A., Szucs S., et al. Role of endothelin-1 in the development of a special type of cardiomyopathy. Clin Sci (Lond) 2002, 103(Suppl 48):272S-275S.